Lung Cancer (NSCLC & SCLC)

Lung cancer is the leading cause of cancer death worldwide. NSCLC treatment has been transformed by EGFR, ALK, ROS1, KRAS, RET, and MET-targeted therapies, as well as immune checkpoint inhibitors. SCLC has seen breakthroughs with DLL3-targeted bispecific agents.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Lung Cancer (NSCLC & SCLC)

• Osimertinib (Tagrisso) — Tyrosine Kinase Inhibitor
• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Nivolumab (Opdivo) — Checkpoint Inhibitor
• Atezolizumab (Tecentriq) — Checkpoint Inhibitor
• Adagrasib (Krazati) — Other
• Sotorasib (Lumakras) — Other
• Alectinib (Alecensa) — Tyrosine Kinase Inhibitor
• Brigatinib (Alunbrig) — ALK Inhibitor
• Lorlatinib (Lorbrena) — ALK Inhibitor
• Crizotinib (Xalkori) — ALK Inhibitor
• Pralsetinib (Gavreto) — Tyrosine Kinase Inhibitor
• Selpercatinib (Retevmo) — Tyrosine Kinase Inhibitor
• Repotrectinib (Augtyro) — Tyrosine Kinase Inhibitor
• Larotrectinib (Vitrakvi) — Tyrosine Kinase Inhibitor
• Tarlatamab (Imdelltra) — Other
• Lurbinectedin (Zepzelca) — Other
• Pemetrexed (Alimta) — Antimetabolite
• Nab-paclitaxel (Paclitaxel Protein-Bound) (Abraxane) — Taxane
• Datopotamab deruxtecan-dlnk (Datroway) — Antibody-Drug Conjugate